R
Robert S. Benjamin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 341
Citations - 24137
Robert S. Benjamin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Sarcoma & Cancer. The author has an hindex of 86, co-authored 325 publications receiving 22177 citations. Previous affiliations of Robert S. Benjamin include University of Texas Health Science Center at Houston & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
Charles D. Blanke,Cathryn Rankin,George D. Demetri,Christopher W. Ryan,Margaret von Mehren,Robert S. Benjamin,A. Kevin Raymond,Vivien H.C. Bramwell,Laurence H. Baker,Robert G. Maki,Michael Tanaka,J. Randolph Hecht,Michael Heinrich,Christopher D.M. Fletcher,John J. Crowley,Ernest C. Borden +15 more
TL;DR: This trial confirms the effectiveness of imatinib as primary systemic therapy for patients with incurable GIST but did not show any advantage to higher dose treatment.
Journal ArticleDOI
Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren,R. Lor Randall,Robert S. Benjamin,Sarah Boles,Marilyn M. Bui,Ernest U. Conrad,Kristen N. Ganjoo,Suzanne George,Ricardo J. Gonzalez,Martin J. Heslin,John M. Kane,Henry B. Koon,Joel L. Mayerson,Martin D. McCarter,Sean V. McGarry,Christian F. Meyer,Richard J. O'Donnell,Alberto S. Pappo,I. Benjamin Paz,Ivy A. Petersen,John D. Pfeifer,Richard F. Riedel,Scott M. Schuetze,Karen D. Schupak,Herbert S. Schwartz,William D. Tap,Jeffrey D. Wayne,Mary Anne Bergman,Jillian L. Scavone +28 more
TL;DR: This portion of the NCCN Guidelines discusses general principles for the diagnosis, staging, and treatment of STS of the extremities, superficial trunk, or head and neck; outlines treatment recommendations by disease stage; and reviews the evidence to support the guidelines recommendations.
Journal ArticleDOI
Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
Jean-Yves Blay,Sylvie Bonvalot,Paolo G. Casali,Haesun Choi,Maria Debiec-Richter,A. P. Dei Tos,Jean-François Emile,Alessandro Gronchi,Pancras C.W. Hogendoorn,Heikki Joensuu,Axel Le Cesne,Joan Mac Clure,Joan Maurel,Ninna Nupponen,Isabelle Ray-Coquard,Peter Reichardt,Raf Sciot,Sigrid Stroobants,Martine Van Glabbeke,Allan T. van Oosterom,George D. Demetri,Ianis Boukovinas,Pierre Meeus,Jim Janinis,Rosella Bertulli,Maurizio Colecchia,Antonella Messina,Elena Tamborini,Seiichi Hirota,Toshirou Nishida,Javier Martin,Andres Poveda,Rafael Ramos,Louis Guillou,Serge Leyvraz,Mike Leahy,Christopher L. Corless,Ronald P. DeMatteo,John Zalcberg,Dolores Knufer,Aage Schultz,Ian Judson,Béatrice Fervers,Binh Bui,Frits van Coevorden,Robert S. Benjamin,Robert G. Maki,Jaap Verweij,Ole S. Nielsen,Michael Heinrich,Bert Van Geel,Larry Baker,Margaret von Mehren,Thor Alvegård,Jean Michel Coindre,Karen H. Antman,Peter Hohenberger,Kirsten Sundby-Hall,Piotr Rutkowski +58 more
TL;DR: In a substantial proportion of patients, stable disease and even increase in tumor size may be associated with pathologic response to imatinib therapy, and available survival data indicate that the survival of these patients is similar to that of patients with conventional tumor response.
Journal ArticleDOI
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
George D. Demetri,Robert S. Benjamin,Charles D. Blanke,Jean-Yves Blay,Paolo G. Casali,Haesun Choi,Christopher L. Corless,Maria Debiec-Rychter,Ronald P. DeMatteo,David S. Ettinger,George A. Fisher,Christopher D.M. Fletcher,Alessandro Gronchi,Peter Hohenberger,Miranda Hughes,Heikki Joensuu,Ian Judson,Axel Le Cesne,Robert G. Maki,Michael A. Morse,Alberto S. Pappo,Peter W.T. Pisters,Chandrajit P. Raut,Peter Reichardt,Douglas S. Tyler,Annick D. Van den Abbeele,Margaret von Mehren,Jeffrey D. Wayne,John Zalcberg +28 more
TL;DR: The GIST Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize the understanding and treatment of GIST.
Journal ArticleDOI
We Should Desist Using RECIST, at Least in GIST
Robert S. Benjamin,Haesun Choi,Homer A. Macapinlac,Michael A. Burgess,Shreyaskumar Patel,Lei L. Chen,Donald A. Podoloff,Chuslip Charnsangavej +7 more
TL;DR: Choi response criteria are reproducible, more sensitive, and more precise than RECIST in assessing the response of GISTs to imatinib mesylate and should be incorporated routinely into future studies of Gist therapy.